APOP - セレクト・バイオテクノロジ― (Cellect Biotechnology Ltd.) セレクト・バイオテクノロジ―



symbol APOP
会社名 Cellect Biotechnology Ltd (セレクト・バイオテクノロジ―)
業種    医療関連(Health Care)
概要 事業概要 --   セレクト・バイオテクノロジ―はイスラエルのバイオ医薬品企業。主に、免疫細胞治療、幹細胞治療、再生医療の開発に従事する。同社のプラットフォ―ムは幹細胞の特性に基づき、アポト―シス(細胞死)誘導エ―ジェントを開発する。動物実験では成果があり、今後は臨床試験やパイプラインの開発に取り組む。本社はクファ―ルサバ。   Cellect Biotechnology Ltd is an emerging biotechnology company engaged in developing a novel technology platform known as ApoGraft that selects stem cells in order to improve the safety and efficacy of regenerative medicine and stem cell therapies.
本社所在地 23 Ha'Taas St. Kfar Saba ISR
市場名 NASDAQ Small Cap
ipoyear 2016年
url www.cellectbio.com
nasdaq_url https://www.nasdaq.com/symbol/apop
adr_tso 6468992
終値(lastsale) 4.8073
時価総額(marketcap) 31098385.2416
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --



   Cellect Biotechnology reports Q1 results  2019-05-21
Cellect Biotechnology (NASDAQ: APOP ): Q1 GAAP EPADS of -$0.16. Cash and cash equivalents of $9.59M Press Release More news on: Cellect Biotechnology Ltd., Earnings news and commentary, Healthcare stocks news, ,
   Cellect Biotechnology Reports First Quarter 2019 Financial and Operating Results  2019-05-21 PR Newswire
TEL AVIV, Israel , May 21, 2019 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today reported financial and operating results for the first quarter ended March 31, 2019 and provided a …
   Cellect Bio up 17% premarket on positive ApoGraft data  2019-03-27
Thinly traded nano cap Cellect Biotechnology (NASDAQ: APOP ) is up 17% premarket on modestly higher volume in reaction to positive preliminary results from a Phase 1/2 clinical trial evaluating its ApoGraft stem cell selection technology in patients undergoing stem cell transpl…
   Cellect Announces Positive Phase I/II Mid-Study Results of Its ApoGraft(TM) Technology  2019-03-27 PR Newswire
TEL AVIV, Israel , March 27, 2019 /PRNewswire/ --Further validating its ApoGrafttechnology, Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production technology, announced positive mid-study data from the Company's Phase I/II study of its A…

 関連キーワード  (― 米国株 セレクト・バイオテクノロジ― APOP Cellect Biotechnology Ltd.)

 twitter  (公式ツイッターやCEOツイッターなど)